These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8376814)

  • 21. Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection.
    Murphy BR; Graham BS; Prince GA; Walsh EE; Chanock RM; Karzon DT; Wright PF
    J Clin Microbiol; 1986 Jun; 23(6):1009-14. PubMed ID: 3754878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of a novel subunit vaccine that protects cotton rats against both human respiratory syncytial virus and human parainfluenza virus type 3.
    Homa FL; Brideau RJ; Lehman DJ; Thomsen DR; Olmsted RA; Wathen MW
    J Gen Virol; 1993 Sep; 74 ( Pt 9)():1995-9. PubMed ID: 8397289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia.
    Groothuis JR; King SJ; Hogerman DA; Paradiso PR; Simoes EA
    J Infect Dis; 1998 Feb; 177(2):467-9. PubMed ID: 9466539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody responses of children to the C-terminal peptide of the SH protein of respiratory syncytial virus and the immunological characterization of this protein.
    Akerlind-Stopner B; Hu A; Mufson MA; Utter G; Norrby E
    J Med Virol; 1993 Jun; 40(2):112-20. PubMed ID: 8360632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses.
    Hu KF; Elvander M; Merza M; Akerblom L; Brandenburg A; Morein B
    Clin Exp Immunol; 1998 Aug; 113(2):235-43. PubMed ID: 9717973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of respiratory syncytial virus (RSV) infected cells by in situ hybridization in the lungs of cotton rats immunized with formalin-inactivated virus or purified RSV F and G glycoprotein subunit vaccine and challenged with RSV.
    Murphy BR; Prince GA; Lawrence LA; Croen KD; Collins PL
    Virus Res; 1990 Jun; 16(2):153-62. PubMed ID: 2385958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
    Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
    J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effective mucosal immunization against respiratory syncytial virus using purified F protein and a genetically detoxified cholera holotoxin, CT-E29H.
    Tebbey PW; Scheuer CA; Peek JA; Zhu D; LaPierre NA; Green BA; Phillips ED; Ibraghimov AR; Eldridge JH; Hancock GE
    Vaccine; 2000 Jun; 18(24):2723-34. PubMed ID: 10781860
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    van Erp EA; van Kasteren PB; Guichelaar T; Ahout IML; de Haan CAM; Luytjes W; Ferwerda G; Wicht O
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28794038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The immunogenicity of subunit vaccines for respiratory syncytial virus after co-formulation with aluminum hydroxide adjuvant and recombinant interleukin-12.
    Hancock GE; Smith JD; Heers KM
    Viral Immunol; 2000; 13(1):57-72. PubMed ID: 10733169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of breast feeding on the development of anti-idiotype antibody response to F glycoprotein of respiratory syncytial virus in infant mice after post-partum maternal immunization.
    Okamoto Y; Tsutsumi H; Kumar NS; Ogra PL
    J Immunol; 1989 Apr; 142(7):2507-12. PubMed ID: 2926142
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.
    Liu X; Liang B; Ngwuta J; Liu X; Surman S; Lingemann M; Kwong PD; Graham BS; Collins PL; Munir S
    J Virol; 2017 Nov; 91(22):. PubMed ID: 28835504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum neutralizing antibody titers of seropositive chimpanzees immunized with vaccines coformulated with natural fusion and attachment proteins of respiratory syncytial virus.
    Hancock GE; Smith JD; Heers KM
    J Infect Dis; 2000 May; 181(5):1768-71. PubMed ID: 10823781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
    Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
    Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Strain-specific serum antibody responses in infants undergoing primary infection with respiratory syncytial virus.
    Hendry RM; Burns JC; Walsh EE; Graham BS; Wright PF; Hemming VG; Rodriguez WJ; Kim HW; Prince GA; McIntosh K
    J Infect Dis; 1988 Apr; 157(4):640-7. PubMed ID: 3346563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protection against respiratory syncytial virus infection by DNA immunization.
    Li X; Sambhara S; Li CX; Ewasyshyn M; Parrington M; Caterini J; James O; Cates G; Du RP; Klein M
    J Exp Med; 1998 Aug; 188(4):681-8. PubMed ID: 9705950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age.
    Glenn GM; Fries LF; Thomas DN; Smith G; Kpamegan E; Lu H; Flyer D; Jani D; Hickman SP; Piedra PA
    J Infect Dis; 2016 Feb; 213(3):411-22. PubMed ID: 26259809
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lack of detectable enhanced pulmonary histopathology in cotton rats immunized with purified F glycoprotein of respiratory syncytial virus (RSV) when challenged at 3-6 months after immunization.
    Hildreth SW; Baggs RR; Brownstein DG; Castleman WL; Paradiso PR
    Vaccine; 1993; 11(6):615-8. PubMed ID: 8322482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection.
    Weltzin R; Traina-Dorge V; Soike K; Zhang JY; Mack P; Soman G; Drabik G; Monath TP
    J Infect Dis; 1996 Aug; 174(2):256-61. PubMed ID: 8699052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.